



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of: Reinhardt, et al.

RECEIVED
MAY 07 2003
10 1700

Application No.: 10/052,123

Group No.: 1714

Filed: 1/17/2002

For: Use Of Transition Metal Complexes Having Oxime Ligands As Bleach Catalysts

Assistant Commissioner for Patent
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is **mandatory**;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

37 C.F.R. section 1.8(a)

37 C.F.R. section 1.10*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"
Mailing Label No. _____ (**mandatory**)

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office (703) ____-____.

Date: 5-2-2003

Ricki D. Barley
Signature
Ricki D. Barley
(type or print name of person certifying)

***WARNING:**

Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).
"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1. ☒ Enclosures accompanying this Information Disclosure Statement are:
 - 1a. ☒ Form PTO-1449.
 - 1b. ☒ Copies of Information Disclosure Statement citations.
 - 1c. ☒ EPO Search Report for application no. EP 02001237, mail date of 3/20/2003.
 - 1d. ☐ Copies of Copending U.S. Applications.
2. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3. ☒ This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.
4. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.
5. ☒ This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6. ☐ This Information Disclosure Statement is filed in conjunction with a Request For Continued Examination. Accordingly, no fee or §1.97(e) Statement is required.

7. ☐ The English language documents identified by reference in the TRANSLATION Section of the foreign patents list of the attached 1449 Form are believed to be a concise statement, or the equivalent or substantial equivalent to the foreign language documents cited in the attached 1449 Form.
8. ☐ In addition to the documents cited, the Office's attention is directed to the following copending U.S. Application Serial Number(s), copies of which are attached for the convenience of the Office:
9. ☒ References G.N. Schrauzer, et al., "Cobalaximes (II) and Vitamin B12r as Oxygen Carriers. Evidence for Monomeric and Dimeric Peroxides and Superoxides", Journal of the American Chemical Society, 92:6, March 25, 1970, pp.1551-1557; and I.W. Pang, et al., "Kinetics of Reversible Binding Carbon Monoxide and Benzyl Isocyanide to Ferrous Dimethylglyoxime Complexes", Inorganic Chemistry, Vol. 16, No. 3, 1977, pp.590-594 that are listed in the EPO Search Report cited herein, were previously submitted, and copies provided with, the Information Disclosure Statement mailed on May 7, 2002.

Respectfully submitted,



Richard P. Silverman
Registration No. 36,277

CUSTOMER NO. 25,255

Clariant Corporation
Industrial Property Department
4000 Monroe Road
Charlotte, North Carolina 28205
Telephone: 704/331-7156
Facsimile: 704/331-7707

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

37 CFR 1.98(b))

ATTY. DOCKET NO.

2001DE401

SERIAL NO.

10/052,123

APPLICANT: Gerd REINHARDT, et al.

FILING DATE: 1/17/02

GROUP: 1714

U.S. PATENT DOCUMENTS

Examiner Initial		Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	3,982,892	9/28/76	Gray	8	111	
	AB	4,100,203	7/11/78	Rutledge	568	730	
	AC						
	AD						
FOREIGN PATENT OR PUBLISHED FOREIGN APPLICATION							
		DOCUMENT NUMBER	PUB. DATE	COUNTRY			TRANSLATION

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication**)

	CA	XP-001231637, Chemical abstract 61:23017, 1/4/1965
	CB	XP-001231636, Hollemann, Wiberg, "Lehrbuch der anorganischen Chemie", 1971, Walter De Gruyter & Co., Berlin, pp. 850
	CC	XP-001231641, Chemical abstract 79:26668, 7/30/1973
	CD	XP-001231642, Chemical abstract 84:58329, 3/1/1976
	CE	XP-001231638, Chemical abstract 88:114519, 4/17/1973
	CF	XP-001231644, English abstract for SU 672854, 3/30/1980
	CG	XP-001231639, Chemical abstract 93:18308, 7/17/1980
	CH	XP-001231643, English abstract for SU 806686, 2/25/1981
	CI	XP-001231640, Chemical abstract 99:224092, 12/26/1993
	CJ	English abstract for JP 01-240831, 9/26/1989
	CK	XP-001231645, English abstract for JP 09-132797, 5/20/1997
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		